Extract

This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma. Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.

Inclusion criteria

• Renal Cell Carcinoma

Country

• Austria
• Bulgaria
• Germany
• Hungary
• Poland
• Romania
• Slovakia
• Spain
• Switzerland
• United Kingdom

Links

• ictrp
• nct